Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

The invention of “blockbuster” weight loss drugs like ... recently reported by the FDA. It received multiple reports of nausea, vomiting, diarrhea, abdominal pain and constipation from compounded ...

Weight loss medications like Ozempic and Wegovy have become increasingly popular over the last few years. For people struggling to lose weight through diet and exercise alone, these medications ...

Getting skinny on weight loss meds takes a fat wad of cash ... appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes ...

Ozempic is approved for the management of type 2 diabetes, but it’s also used off-label to support weight loss ... the FDA approved to manage type 2 diabetes. Its active ingredient, semaglutide ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and ... by the US Food and Drug Administration (FDA) in June 2021 and in the EU in January 2022.